3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
153
Carboplatin
123
Bevacizumab
87
Cisplatin
66
pembrolizumab
58
Taxes
51
Gemcitabine
51
liposomal doxorubicin
39
Topotecan
37
olaparib
31
Immunoglobulin G
27
Disulfides
26
Cyclophosphamide
24
Brachytherapy
22
Docetaxel
21
human papillomavirus vaccine, L1 type 16, 18
20
niraparib
19
Platinum
19
Nivolumab
18
Magnetic Resonance Spectroscopy
18
1,2-diaminocyclohexaneplatinum II citrate
18
rucaparib
17
durvalumab
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
16
Doxorubicin
16
Radiotherapy, Intensity-Modulated
14
Radiation
13
Albumin-Bound Paclitaxel
13
fludarabine phosphate
12
fludarabine
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
tinostamustine
×
Gynecologic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts